中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2009年
2期
221-222
,共2页
肝炎,丙型,慢性%干扰素类%聚乙烯二醇类
肝炎,丙型,慢性%榦擾素類%聚乙烯二醇類
간염,병형,만성%간우소류%취을희이순류
Hepatitis C,chrinic%Interferons%Polyethylene glycols
目的 观察聚乙二醇干扰素(PEG-IFNα-2a)治疗慢性丙型肝炎的疗效及安全性.方法 60例慢性丙型肝炎患者,按治疗方案的不同分为:治疗组30例、对照组30例,治疗组给予PEG-IFNα-2a 180 μg或135 μg,每周一次,对照组给予α-干扰素(IFNα-1b)50 μg,隔天一次,两组均联合利巴韦林(900 mg/d)治疗,疗程48周,随访24周.观察两组患者生化应答及病毒学应答情况.结果 治疗组病毒学应答率分别为:早期病毒学应答21例(70.0%)、治疗结束时病毒学应答23例(76.3%)、持续病毒学应答16例(53.3%),与对照组的9(30.0%)、10(33.3%)、6(20.0%)例相比较,差异均有统计学意义(均P＜0.01);两组生化应答未见明显差异(均P＞0.05);不良反应发生率差异无统计学意义(P＞0.05).结论 PEG-IFNα-2a对慢性丙型肝炎患者的疗效优于α-1bI FN,且具有较好的安全性和耐受性.
目的 觀察聚乙二醇榦擾素(PEG-IFNα-2a)治療慢性丙型肝炎的療效及安全性.方法 60例慢性丙型肝炎患者,按治療方案的不同分為:治療組30例、對照組30例,治療組給予PEG-IFNα-2a 180 μg或135 μg,每週一次,對照組給予α-榦擾素(IFNα-1b)50 μg,隔天一次,兩組均聯閤利巴韋林(900 mg/d)治療,療程48週,隨訪24週.觀察兩組患者生化應答及病毒學應答情況.結果 治療組病毒學應答率分彆為:早期病毒學應答21例(70.0%)、治療結束時病毒學應答23例(76.3%)、持續病毒學應答16例(53.3%),與對照組的9(30.0%)、10(33.3%)、6(20.0%)例相比較,差異均有統計學意義(均P＜0.01);兩組生化應答未見明顯差異(均P＞0.05);不良反應髮生率差異無統計學意義(P＞0.05).結論 PEG-IFNα-2a對慢性丙型肝炎患者的療效優于α-1bI FN,且具有較好的安全性和耐受性.
목적 관찰취을이순간우소(PEG-IFNα-2a)치료만성병형간염적료효급안전성.방법 60례만성병형간염환자,안치료방안적불동분위:치료조30례、대조조30례,치료조급여PEG-IFNα-2a 180 μg혹135 μg,매주일차,대조조급여α-간우소(IFNα-1b)50 μg,격천일차,량조균연합리파위림(900 mg/d)치료,료정48주,수방24주.관찰량조환자생화응답급병독학응답정황.결과 치료조병독학응답솔분별위:조기병독학응답21례(70.0%)、치료결속시병독학응답23례(76.3%)、지속병독학응답16례(53.3%),여대조조적9(30.0%)、10(33.3%)、6(20.0%)례상비교,차이균유통계학의의(균P＜0.01);량조생화응답미견명현차이(균P＞0.05);불량반응발생솔차이무통계학의의(P＞0.05).결론 PEG-IFNα-2a대만성병형간염환자적료효우우α-1bI FN,차구유교호적안전성화내수성.
Objective To investigate the efficacy of PEG-INF alpha-2a(PEG-INF-2a)on patients with chronic hepatitis C.Methods 60 patients with hepatitis C were included in this study.30 patients were treated with PEGINF-2a(180μg or 135μg/week)and RBV 900mg/d,30 patients were treated with IFNα-2a(5 MIU/qod)and RBV 900 mg/d.The time of treatment was 48 weeks,and all the patients were followed up for 24 weeks after treatment.There was no significant difference between the two groups in pretreatment HCV-RNA,HCV genotype and other clinical data.The main parameters to evaluate the efficacy were virological and biochemical responses.The side effects were intensively observed.Results Sustained vimlogical response(SVR)rate in PEG-IFNα-2a group was significantly higher than that in IFNα-2a group(56.5%and 19.5%respectively,P＜0.01).As the patients were divided according to HCV genotype 1 and high virus load.the SVR rate of PEG-IFNα-2a group Was higher than IFNα-2a group(P＜0.01).However,there was no significant difference between two groups in the patients with non-genotype 1 and low viral load(P=0.664,0.116).Similar side-effects were observed in PEG IFNα-2a group and IFNα-2a group,but the rate of weisht decline and the degree of leukocyte decrease were more significant in PEG IFNα-2a group than in IFNα-2a group(P＜0.01).Conclusion The efficacy of PEG IFNα-2a in the treatment of chromic hepatitis C is superior to that of conventional IFNα-2a,PEG-IFNα-2a had good tolerance and safety profiles.
